Biophysical and structural studies on the capsid protein of the human immunodeficiency virus type 1: a new drug target?
New therapeutic agents are necessary against HIV due to the rapid emergence of drug-resistant variants of the virus, which has yielded therapeutic strategies partially ineffective. Assembly can be considered as a good target for antivirals since it depends only on repetitive weak protein-protein interactions, and probably disruption of a small part of these interactions is sufficient to suppress infectivity in a dominant-negative effect. We propose the capsid protein of HIV-1 as a potential candidate.
Neira
José L
JL
Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Elche (Alicante) 03202, Spain. jlneira@umh.es
D036022:Capsid Proteins / Q000737:chemistry*; D019281:Dimerization; D015195:Drug Design; D015497:HIV-1 / Q000378:metabolism*; D011485:Protein Binding; D011487:Protein Conformation; D017510:Protein Folding
D036022:Capsid Proteins